Editorials

Community acquired pneumonia in primary care

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7549.1045 (Published 04 May 2006) Cite this as: BMJ 2006;332:1045
  1. Herman Goossens (Herman.Goossens@uza.be), professor of microbiology,
  2. Paul Little, professor of primary care research
  1. Laboratory of Medical Microbiology, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium
  2. University of Southampton, Aldermoor Health Centre, Southampton S016 55T

    Doctors cannot target antibiotics and reduce resistance until new diagnostic tests prove feasible and affordable at the point of care

    In Europe 90-95% of antibiotic use occurs outside hospitals, and community acquired lower respiratory tract infections (LRTI) are the leading reason for prescribing antibiotics.1 Few conditions in medicine are so controversial or have resulted in so much promiscuity in prescribing. The escalating resistance of common bacterial respiratory pathogens to antibiotics in the community2 will be contained only by reducing prescribing in everyday practice and targeting antibiotics selectively. We have known this for a long time. But it is difficult to target antibiotics appropriately, particularly in LRTI.

    Several problems underlie this clinical uncertainty about which patients with LRTI benefit from antibiotics and which do not. The update on diagnosis and management of pneumonia by Hoare and Lim in this week's BMJ nicely illustrates this controversy (p 1077).3 Results of trials indicate that most patients with initially uncomplicated infection will probably have limited benefit, but this evidence is scant: the relevant …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe